Vietnam's rapidly developing precision medicine ecosystem is creating new opportunities for liquid biopsy as healthcare providers look for less invasive and increasingly sophisticated methods of detecting, profiling and monitoring cancer.
While there is currently no independently verified published valuation for Vietnam's overall liquid biopsy market, analysis of the country's cancer diagnostics sector and Asia-Pacific liquid biopsy market suggests that Vietnam's market could be worth approximately US$25–40 million in 2025, potentially reaching US$55–85 million by 2030.
Liquid biopsy represents one of the most important developments in precision oncology. Instead of requiring a conventional surgical tissue biopsy, liquid biopsy analyses cancer-related material circulating within blood or other body fluids.
The technology can detect biomarkers including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free DNA (cfDNA), RNA and extracellular vesicles such as exosomes. This allows clinicians to gain molecular information about a tumour through a minimally invasive blood sample.
Its applications are expanding across the cancer pathway, including early cancer detection, molecular profiling, treatment selection, monitoring response to therapy, identification of resistance mutations and detection of minimal residual disease or recurrence.
A growing opportunity within Vietnam's cancer diagnostics sector
Vietnam's wider cancer diagnostics market provides an important indication of the potential opportunity. IMARC Group values the country's Cancer Diagnostics Market at US$887.2 million in 2025, forecasting it to reach US$1.60 billion by 2034. Rising cancer incidence, increased awareness of early detection and advances in diagnostic technologies are identified as major drivers.
Liquid biopsy is particularly relevant to the growth of precision medicine and companion diagnostics. Vietnam's companion diagnostics market reached US$50.1 million in 2025 and is forecast to reach US$127.6 million by 2034, representing a 10.61% CAGR. IMARC specifically identifies rapid adoption of liquid biopsy and other non-invasive diagnostics, personalised medicine and NGS-based companion diagnostics as factors driving this expansion.
Next-generation sequencing is also transforming the sector. NGS enables laboratories to analyse multiple cancer-related genetic alterations simultaneously from circulating tumour DNA, potentially providing clinicians with a detailed molecular profile that can help guide targeted treatment.
From cancer diagnosis to continuous disease monitoring
One of liquid biopsy's most important advantages is its potential to be repeated throughout treatment.
Traditional tissue biopsy captures information from a tumour at a particular moment and location. Cancer can evolve over time, however, particularly under the selective pressure of treatment. Repeated blood-based testing can potentially provide clinicians with a more dynamic picture of how the disease is changing.
This creates significant opportunities in treatment monitoring, therapy selection and detection of recurrence, as well as early-stage cancer screening.
Lung cancer represents an important potential application in Vietnam. Dedicated Vietnam market research already covers liquid biopsy for both small-cell and non-small-cell lung cancer using circulating tumour cells, ctDNA, exosomes and RNA.
Asia-Pacific liquid biopsy adoption accelerates
The regional market is expanding quickly. Grand View Research reports that Asia-Pacific generated approximately US$1.99 billion in liquid biopsy revenue in 2025 and forecasts the market to reach approximately US$5.30 billion by 2033, representing annual growth of around 13%. Blood-based testing represents the dominant sample type.
Other research providers forecast even faster expansion. BIS Research valued Asia-Pacific at US$708.1 million in 2024 and expects it to reach US$2.92 billion by 2033, a CAGR of approximately 17%. The variation demonstrates how significantly market definitions differ, but there is broad agreement that liquid biopsy represents a rapidly expanding area of cancer diagnostics.
The global outlook is similarly strong. MarketsandMarkets forecasts the liquid biopsy market to reach US$7.05 billion by 2030, with an 11.8% CAGR between 2025 and 2030. Its market definition encompasses kits, instruments, ctDNA, cfDNA and CTC technologies using NGS and PCR across cancers including lung, breast and prostate cancer.
Opportunities across the laboratory and life sciences ecosystem
Growth in liquid biopsy creates commercial opportunities far beyond the diagnostic tests themselves. The technology requires an increasingly sophisticated ecosystem incorporating NGS platforms, PCR systems, automated sample preparation, DNA extraction, laboratory automation, bioinformatics, AI-powered genomic analysis, reagents and specialist laboratory services.
International companies active in the sector include Roche, Guardant Health, QIAGEN, Illumina, Thermo Fisher Scientific, Exact Sciences, Natera, Bio-Rad Laboratories and NeoGenomics Laboratories.
As Vietnam expands its cancer diagnostics, genomics and precision medicine capabilities, liquid biopsy has the potential to become an increasingly important component of the country's oncology infrastructure.
For diagnostic companies, sequencing technology manufacturers, laboratory equipment suppliers, biotechnology businesses and pharmaceutical organisations, Vietnam therefore represents an early-stage but potentially fast-growing market at the intersection of cancer diagnostics, genomics and personalised medicine.